AbbVie Inc. $ABBV Shares Purchased by Signal Advisors Wealth LLC

Signal Advisors Wealth LLC increased its position in AbbVie Inc. (NYSE:ABBV) by 16.0% during the third quarter, HoldingsChannel.com reports. The firm owned 26,598 shares of the company’s stock after acquiring an additional 3,660 shares during the quarter. Signal Advisors Wealth LLC’s holdings in AbbVie were worth $6,958,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of ABBV. Affinity Capital Advisors LLC grew its holdings in shares of AbbVie by 10.9% during the third quarter. Affinity Capital Advisors LLC now owns 4,168 shares of the company’s stock valued at $1,152,000 after buying an additional 408 shares during the last quarter. Spartan Planning & Wealth Management raised its holdings in AbbVie by 13.7% in the 3rd quarter. Spartan Planning & Wealth Management now owns 2,989 shares of the company’s stock worth $782,000 after acquiring an additional 359 shares during the last quarter. Clay Northam Wealth Management LLC purchased a new position in AbbVie in the 3rd quarter worth approximately $205,000. Lineweaver Wealth Advisors LLC raised its holdings in AbbVie by 3.3% in the 3rd quarter. Lineweaver Wealth Advisors LLC now owns 17,940 shares of the company’s stock worth $4,693,000 after acquiring an additional 573 shares during the last quarter. Finally, Accel Wealth Management lifted its position in AbbVie by 3.0% in the 3rd quarter. Accel Wealth Management now owns 5,518 shares of the company’s stock valued at $1,443,000 after acquiring an additional 160 shares in the last quarter. 70.23% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

ABBV has been the topic of several recent analyst reports. Royal Bank Of Canada reiterated an “outperform” rating and set a $280.00 target price on shares of AbbVie in a research note on Tuesday. Piper Sandler lifted their target price on AbbVie from $298.00 to $303.00 and gave the stock an “overweight” rating in a report on Thursday, August 20th. Morgan Stanley boosted their price target on AbbVie from $296.00 to $310.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 7th. Canaccord Genuity Group upped their price target on AbbVie from $282.00 to $290.00 and gave the company a “buy” rating in a report on Monday, August 3rd. Finally, Leerink Partners upped their price target on AbbVie from $245.00 to $279.00 and gave the company an “outperform” rating in a report on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat.com, AbbVie has an average rating of “Moderate Buy” and a consensus price target of $277.18.

AbbVie Stock Down 2.2%

Shares of ABBV stock opened at $274.82 on Wednesday. The company has a 50 day moving average price of $260.41 and a 200-day moving average price of $237.87. AbbVie Inc. has a 52 week low of $190.75 and a 52 week high of $283.43. The firm has a market capitalization of $485.55 billion, a PE ratio of 77.63, a P/E/G ratio of 1.28 and a beta of 0.24.

AbbVie (NYSE:ABBV) last issued its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, beating analysts’ consensus estimates of $3.61 by $0.04. The company had revenue of $16.99 billion for the quarter, compared to the consensus estimate of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The firm’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Analysts anticipate that AbbVie Inc. will post 13.95 earnings per share for the current year.

AbbVie Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be paid a dividend of $1.73 per share. The ex-dividend date is Thursday, October 15th. This represents a $6.92 dividend on an annualized basis and a yield of 2.5%. AbbVie’s payout ratio is currently 195.48%.

Insiders Place Their Bets

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the stock in a transaction on Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the transaction, the executive vice president directly owned 74,430 shares of the company’s stock, valued at $18,607,500. This represents a 30.53% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 0.06% of the company’s stock.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Potential Q3 revenue beat: RBC expects AbbVie to exceed third-quarter revenue estimates, driven by continued momentum for immunology drugs Skyrizi and Rinvoq, as well as psychiatric medicine Vraylar. This supports expectations that newer products can offset Humira’s loss of exclusivity. AbbVie Poised for Q3 Top-Line Beat Driven by Rinvoq, Skyrizi, and Vraylar Therapies, RBC Says
• Positive Sentiment: Encouraging Skyrizi data: New Phase 3 AFFIRM results showed favorable clinical and endoscopic outcomes for subcutaneous Skyrizi in patients with moderately to severely active Crohn’s disease. The data could strengthen Skyrizi’s position in a major growth market and expand AbbVie’s immunology opportunity. AbbVie Presents New Phase 3 AFFIRM Data
• Positive Sentiment: Pipeline and analyst support: Recent Crohn’s disease data for Skyrizi and Rinvoq, cancer-related regulatory milestones for Temab-A, and early metabolic-treatment data are improving the outlook for AbbVie’s post-Humira growth. RBC reaffirmed its “Outperform” rating, although its target implies only limited additional upside. AbbVie Could Be 44% Below Fair Value on Fresh Pipeline Wins
• Neutral Sentiment: Strategic expansion: AbbVie’s acquisition of Apogee and related leadership moves highlight the company’s effort to replenish its pipeline through business development, but the long-term financial impact remains uncertain. Biotech Builder Paragon Imports Apogee’s Top Brass After AbbVie Buyout
• Negative Sentiment: Valuation and execution risks: At a high earnings multiple near its recent peak, ABBV may be vulnerable to profit-taking even with positive clinical news. Investors also remain concerned about Humira’s ongoing sales erosion, increasing immunology competition, and whether Skyrizi and Rinvoq can sustain their rapid growth.

AbbVie Profile

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health.

The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.